Universe Competitors

Stocks . USA . 
Stock . Universe Pharmaceuticals
UPC Stock  USD 3.70  0.12  3.14%   
Universe Pharmaceuticals competes with Sphere Entertainment, Ambipar Emergency, Logan Ridge, Spyre Therapeutics, and Radcom; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing Universe Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Universe Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Universe Pharmaceuticals Correlation with its peers.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Universe Pharmaceuticals competition on your existing holdings.
  
Build AI portfolio with Universe Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.193.7013.60
Details
Intrinsic
Valuation
LowRealHigh
0.163.1113.01
Details
Naive
Forecast
LowNextHigh
0.083.7713.67
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.413.994.56
Details

Universe Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Universe Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Universe and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Universe Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
DH
+ 0.92
SPHR
RDCM
+ 0.89
SPHR
KVHI
+ 0.83
SPHR
DH
+ 0.8
RDCM
KVHI
+ 0.78
DH
KVHI
+ 0.74
RDCM
  
High negative correlations   
SYRE
- 0.24
LRFC
ZH
- 0.17
LRFC

Risk-Adjusted Indicators

There is a big difference between Universe Stock performing well and Universe Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Universe Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Universe Pharmaceuticals Competitive Analysis

The better you understand Universe Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Universe Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Universe Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
UPC SPHR AMBI LRFC SYRE RDCM DH ZH KVHI
 3.14 
 3.70 
Universe
 2.21 
 43.43 
Sphere
 0.84 
 4.72 
Ambipar
 0.48 
 18.85 
Logan
 1.68 
 15.76 
Spyre
 1.33 
 13.76 
Radcom
 0.25 
 4.03 
Definitive
 6.30 
 4.39 
Zhihu
 1.50 
 5.41 
KVH
Market Volatility
(90 Days Market Risk)
Dangerous
Not too volatile
Risky
Not too volatile
Somewhat reliable
Somewhat reliable
Very risky
Moderately volatile
Somewhat reliable
Market Performance
(90 Days Performance)
Modest
Good
Weak
Weak
OK
Good
Good
OK
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
About Average
About Average
Below Average
Below Average
Below Average
Low
Quite High
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
5.06
N/A
4.03
3.46
N/A
4.87
3.32
3.4
2.57
Net Asset
67.95 M
4.79 B
5.77 B
192.67 M
608.48 M
130.57 M
1.09 B
5.73 B
155.08 M
Profit Margin
-0.38
-0.48
-0.0063
-0.35
N/A
0.14
-2.06
-0.0051
-0.0873
EBITDA
(7.53 M)
(23.86 M)
661.89 M
8.87 M
(207.97 M)
3.71 M
(567.24 M)
(459.13 M)
2.67 M
Operating Margin
-0.62
-0.27
0.11
0.59
N/A
0.0881
-0.12
-0.0721
-0.0883
Current Valuation
(37.46 M)
2.56 B
765.27 M
141.85 M
796.82 M
124.98 M
412.52 M
(257.18 M)
58.47 M
Price To Book
0.0458
0.73
0.99
0.64
2.91
2.21
1.34
0.67
0.77
Retained Earnings
(10.17 M)
11.39 M
342.09 M
(103.79 M)
(972.43 M)
(62.94 M)
(640.57 M)
(8.88 B)
(12.75 M)
Current Asset
N/A
N/A
54.85 M
N/A
N/A
16.06 M
N/A
N/A
115.09 M
Beta
1.51
1.65
0.44
0.76
2.73
0.74
1.58
0.18
0.81
Number Of Employees
225
1.08 K
7.43 K
5
73
307
782
1.89 K
75
Shares Outstanding
563.34 K
29.13 M
16.2 M
2.66 M
60.35 M
16.03 M
107.34 M
82.56 M
19.6 M
Cash Flow From Operations
(9.51 M)
(19.66 M)
427.15 M
13.94 M
(157.41 M)
11.39 M
58.2 M
(280.19 M)
(13.17 M)
Annual Yield
N/A
N/A
N/A
0.0758
N/A
N/A
N/A
N/A
N/A
Total Debt
5.86 M
1.52 B
3.44 B
7.06 M
84.56 M
3.4 M
253.11 M
19.13 M
1.23 M
Return On Equity
-0.24
-0.16
0.037
-0.0858
-0.66
0.0935
-0.9
-0.0031
-0.0678
Return On Asset
-0.0914
-0.0262
0.0601
0.0393
-0.25
0.0246
-0.0043
-0.0316
-0.0359
Number Of Shares Shorted
32.74 K
7.46 M
14.25 K
1.52 K
12.59 M
91.88 K
4.63 M
1.14 M
58.26 K
Book Value Per Share
1061.17
59.75
26.15
29.66
5.42
6.23
2.94
50.26
6.98
Current Liabilities
N/A
N/A
13.6 M
N/A
N/A
6.42 M
N/A
N/A
43.56 M
Total Asset
67.95 M
4.79 B
5.77 B
192.67 M
608.48 M
130.57 M
1.09 B
5.73 B
155.08 M
Debt To Equity
0.072
N/A
0.03
1.0
N/A
0.019
0.19
0.019
0.018
Short Ratio
0.24
12.31
1.97
0.15
26.96
1.61
7.27
6.57
2.01
Target Price
N/A
51.18
11.16
24.0
53.9
18.0
4.1
5.68
7.0
Last Dividend Paid
N/A
N/A
N/A
1.38
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
0.04
94.24
7.24
30.23
91.29
53.9
96.93
28.8
59.77
Market Capitalization
2.08 M
1.56 B
318.59 M
50.06 M
951.17 M
220.56 M
432.59 M
403.66 M
106.03 M
Price To Earning
3.02
N/A
-8.1
30.63
N/A
28.2
N/A
N/A
4.2
Price To Earnings To Growth
N/A
N/A
N/A
-1.44
N/A
11.08
1.03
N/A
3.35
Price To Sales
0.0905
1.52
0.0981
2.44
650.22
3.47
1.74
0.12
0.96
Net Income
(8.73 M)
(200.65 M)
(1.99 M)
(29 K)
(208.02 M)
6.97 M
(591.45 M)
(168.97 M)
(11.05 M)
Earnings Per Share
-639.5
-9.79
-0.07
-2.72
-3.06
0.53
-4.41
-0.03
-0.5
Shares Owned By Insiders
0.61
5.76
84.26
10.3
8.71
14.84
9.0
11.59
18.89
Revenue
23.02 M
1.03 B
3.29 B
5.26 M
886 K
61.01 M
252.2 M
3.6 B
113.83 M
Working Capital
31.32 M
(507.98 M)
771.21 M
N/A
554.41 M
89.29 M
209.01 M
3.96 B
106.7 M
Cash And Equivalents
28.58 M
N/A
52.8 M
29.49 M
N/A
73.06 M
347.87 M
4.53 B
15.55 M
Cash Per Share
1.31
N/A
2.93
10.88
N/A
5.05
3.46
9.19
0.81
Gross Profit
6.07 M
421.37 M
478.78 M
20.54 M
(169.48 M)
47.77 M
206.82 M
2.09 B
32.74 M
Day Typical Price
3.72
43.29
4.84
18.86
15.88
13.73
4.03
4.3
5.45
Accumulation Distribution
0.0445
0.037
0.0784
0.0189
0.0614
0.0188
0.0318
0.0769
0.0359
Market Facilitation Index
0.17
1.63
0.4
0.36
1.01
0.26
0.13
0.34
0.2
Daily Balance Of Power
(0.71)
0.5767
(0.10)
(0.25)
0.2574
0.6923
0.0769
0.7647
0.4
Period Momentum Indicator
(0.12)
0.94
(0.04)
(0.09)
0.26
0.18
0.01
0.26
0.08
Rate Of Daily Change
0.97
1.02
0.99
1.0
1.02
1.01
1.0
1.06
1.02
Day Median Price
3.74
43.22
4.9
18.87
15.94
13.71
4.03
4.25
5.47
Price Action Indicator
(0.1)
0.68
(0.20)
(0.07)
(0.04)
0.14
0.01
0.27
(0.02)
Relative Strength Index
45.54
66.27
50.82
57.38
53.82
60.0
67.32
64.51
57.57
Coefficient Of Variation
1325.35
495.3
5120.53
5939.36
927.14
601.43
550.15
718.28
1435.45
Mean Deviation
6.5
2.86
3.58
1.13
3.3
2.25
2.56
2.14
1.23
Jensen Alpha
0.6599
0.8689
0.0913
0.0436
0.556
0.4731
0.8605
0.4037
0.125
Total Risk Alpha
0.1194
0.5716
(0.22)
(0.1)
0.1973
0.2838
0.5581
0.2057
0.0033
Sortino Ratio
0.0808
0.2125
(0)
(0.05)
0.079
0.1283
0.2747
0.0965
0.0085
Downside Variance
61.85
11.8
29.02
2.83
23.12
7.8
7.52
8.37
3.43
Standard Deviation
9.9
4.17
4.94
1.94
4.56
2.83
4.76
2.81
1.83
Kurtosis
5.01
5.3
0.401
13.1
1.42
0.0083
27.57
0.0307
2.22
Potential Upside
15.58
6.05
9.2
2.28
7.6
5.42
5.06
6.13
4.32
Treynor Ratio
0.9744
(2.27)
(1.85)
(0.11)
(0.66)
(3.63)
(15.72)
(1.69)
(1.59)
Maximum Drawdown
68.05
26.82
24.21
11.85
24.95
12.44
36.59
11.54
9.24
Variance
97.97
17.38
24.44
3.77
20.77
8.0
22.64
7.88
3.35
Market Risk Adjusted Performance
0.9844
(2.26)
(1.84)
(0.10)
(0.65)
(3.62)
(15.71)
(1.68)
(1.58)
Risk Adjusted Performance
0.1314
0.3354
0.0386
0.0291
0.1823
0.2754
0.303
0.2312
0.1147
Skewness
1.19
1.31
0.0607
2.22
(0.23)
(0.08)
4.41
0.1558
0.5059
Semi Deviation
7.15
2.83
4.39
1.52
4.41
2.28
1.8
2.28
1.46
Information Ratio
0.0642
0.1751
(0)
(0.04)
0.0833
0.1268
0.1583
0.0994
0.0086
Value At Risk
(12.80)
(4.71)
(7.71)
(3.02)
(6.75)
(3.93)
(4.00)
(4.02)
(2.38)
Expected Short fall
(8.18)
(3.31)
(4.54)
(1.33)
(3.49)
(2.48)
(3.14)
(2.32)
(1.60)
Downside Deviation
7.86
3.43
5.39
1.68
4.81
2.79
2.74
2.89
1.85
Semi Variance
51.07
8.03
19.25
2.3
19.42
5.2
3.23
5.19
2.12

Universe Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Universe Pharmaceuticals Competition

Universe Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Universe Pharmaceuticals in relation to its competition. Universe Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Universe Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Universe Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Universe Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Universe Pharmaceuticals position

In addition to having Universe Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Education Thematic Idea Now

Education
Education Theme
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:
How To Invest In Universe
Details
Is Universe Stock a good investment?
Details
What is Universe Pharmaceuticals' Net Worth?
Details
Largest Pharmaceutical Products Companies
View
Largest Drug Manufacturers - Specialty & Generic Companies
View
Check out Universe Pharmaceuticals Correlation with its peers.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY